The predominant pathway activations include CARD11 NF-κB-dependent activation in ∼10% of cases [5] and Myd88 mutations observed in ∼39% of cases [6], both contributing to constitutive NF-κB activity in ABC DLBCL. The gene discussed is NFKB1; the disease is diffuse large B-cell lymphoma.